Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating

Leerink Partners analyst David Risinger has maintained their bullish stance on GPCR stock, giving a Buy rating on May 9.

David Risinger has given his Buy rating due to a combination of factors that highlight Structure Therapeutics, Inc.’s promising pipeline and financial stability. The company reported an operating expense that exceeded expectations, indicating a robust investment in its research and development efforts. Notably, Structure Therapeutics is advancing its small-molecule amylin candidate, ACCG-2671, with new preclinical data to be presented at the upcoming American Diabetes Association Scientific Sessions. Additionally, the company’s exploration of GLP-1 receptor agonists in new indications such as Parkinson’s disease further underscores its innovative approach.
Moreover, Structure Therapeutics maintains a strong cash position, with a balance of $836.9 million as of March 31, 2025, which is expected to support operations through at least 2027. This financial health provides a solid foundation for ongoing and future clinical trials, including the anticipated Phase 2b and Phase 2 ACCESS trials for aleniglipron. The company’s strategic plans to select additional development candidates in the coming years, coupled with the expected release of Phase 1 data from its idiopathic pulmonary fibrosis program, reinforce the potential for significant advancements and value creation.

In another report released on May 9, Piper Sandler also maintained a Buy rating on the stock with a $93.00 price target.